drugset
drugset / Trial / NCT03275857

Cisplatin in Castration Resistant Prostate Cancer

NCT03275857 ↗

Phase 0 Completed 12 enrolled University of Rochester Roswell Park Cancer Institute · collab
NaSingle-groupOpen-labelTreatment

Summary

It is hypothesized that treatment with cisplatin will reverse emerging refractoriness to enzalutimide in patients with CRPC by affecting AR function.

Timeline

Start
2018-09-21
Primary completion
2023-07-31
Completion
2023-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified — Intravenous

Indications

prostate cancer